Technology

QRxPharma’s patented Dual Opioid® technology combines two opioids in a unique, fixed ratio which has been shown to provide significant pain relief with a reduction of total opioid dose and side effects.

QRxPharma’s lead product candidate, MoxDuo® IR, an immediate release (IR) formulation combining morphine and oxycodone, entered Phase 3 clinical trials for the treatment of moderate to severe pain in 2007.  The Company expects to complete clinical testing and submit a New Drug Application (NDA) in 2010. The Company has also initiated Phase 2 trials with an intravenous (IV) MoxDuo® IV for the management of moderate to severe pain.  Additionally, a controlled release (CR) formulation of morphine and oxycodone, MoxDuo® CR, is slated to initiate Phase 1 studies in 2009.

QRxPharma believes that our combination of existing opioids, whose individual characteristics have been known for many decades, has the potential to provide a lower dosage format to achieve pain relief with fewer side effects and much lower associated risks than existing therapies. According to a report by Datamonitor in 2008, the most common unmet needs in the market for moderate to severe pain are reduced side effects, improved therapeutic effect, and the availability of different opioid formulations.  QRxPharma therefore believes that its drug will offer doctors who prescribe pain drugs a unique and differentiated value proposition.

QRxPharma extends its CNS product portfolio into neurologic disorders such as Dystonia, Parkinson’s Disease and Alzheimer's Disease, with breakthrough technology from the University of Alabama (UofA) on the modulation of Torsin, a key protein for normal cellular function in the brain. In preclinical studies, we have shown that existing drugs and our portfolio of New Chemical Entities enhance activation of Torsin and may ameliorate these diseases at a causative level.

Our program offers the opportunity to provide neuroprotection and prevent disease progression in these three therapeutic areas where there are currently no disease-modifying agents available. This has the potential to answer a critical unmet need in neurotherapeutics.